Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer
We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.
Authors
- William L. Redmond (ORCID: https://orcid.org/0000-0002-2572-1731)
- James H. Imatani
- Zheng Topp
- Staci Mellinger
- Nicole Moxon (ORCID: https://orcid.org/0000-0003-4376-9082)
- Nicole Fredrich
- Tyler J. Nielsen (ORCID: https://orcid.org/0000-0002-9576-2838)
- S. Aliabadi-Wahle
- Sasha E. Stanton (ORCID: https://orcid.org/0000-0002-4300-551X)
- Alan Su (ORCID: https://orcid.org/0009-0003-8464-5542)
- Douglas Hanes (ORCID: https://orcid.org/0000-0001-7131-3096)
- Philippa Newell
- Kristen P. Massimino
- Wesley Rosales (ORCID: https://orcid.org/0000-0002-6381-9844)
- Maritza Martel
- Alison Conlin
- Zhaoyu Sun
- Erin C. Hong
- Tracy Kelly
- David B. Page
- Yaping Wu
- Michael Simanonok
Institutions
- Providence Portland Medical Center (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1038/s41523-026-00925-0
- Primary Topic
- Lymphatic System and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00